| Host: |
Rabbit |
| Applications: |
WB, ELISA |
| Reactivity: |
Human, Mouse, Rat |
| Note: |
FOR RESEARCH USE ONLY (RUO). |
| Short Description: |
Rabbit polyclonal antibody anti-Acetyl-Cyclin-Dependent Kinase Inhibitor 1c-Lys278 (241-290) is suitable for use in Western Blot and ELISA research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS, 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit anti-serum by affinity-chromatography. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:500-1:2000ELISA 1:20000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
CDKN1C |
| Gene ID: |
1028 |
| Uniprot ID: |
CDN1C_HUMAN |
| Immunogen Region: |
241-290 |
| Specificity: |
Acetyl-CDKN1C-Lys278 polyclonal antibody (Cyclin-Dependent Kinase Inhibitor 1c) binds to endogenous Cyclin-Dependent Kinase Inhibitor 1c at the amino acid region 241-290. |
| Immunogen: |
The antiserum was produced against synthesized Acetyl-peptide derived from human p57Kip2 around the Acetylation site of Lys278 at amino acid range 241-290 |
| Function | Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non-proliferative state throughout life. |
| Protein Name | Cyclin-Dependent Kinase Inhibitor 1cCyclin-Dependent Kinase Inhibitor P57P57kip2 |
| Database Links | Reactome: R-HSA-69231Reactome: R-HSA-9661069 |
| Cellular Localisation | Nucleus |
| Alternative Antibody Names | Anti-Cyclin-Dependent Kinase Inhibitor 1c antibodyAnti-Cyclin-Dependent Kinase Inhibitor P57 antibodyAnti-P57kip2 antibodyAnti-CDKN1C antibodyAnti-KIP2 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
